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Abstract
Background: The direct agglutination test (DAT) has proved to be a very important sero-
diagnostic tool combining high levels of intrinsic validity and ease of performance. Otherwise, fast
agglutination screening test (FAST) utilises only one serum dilution making the test very suitable
for the screening of large populations.
Results: We have tested FAST and DAT for the detection anti-Leishmania antibodies in serum
samples from patients with American visceral (AVL) and cutaneous leishmaniases (ACL) in Minas
Gerais State, Brazil. The DAT on serum and blood samples of confirmed AVL patients found all
samples positive at a serum dilution of ≥  1:800. This dilution was subsequently used as cut off value
in the study. The blood and serum samples of these confirmed patients could also be clearly read
in FAST using a 1:100 dilution with the same high sensitivity. DAT and FAST were not able to detect
significant amounts of antibodies in samples from ACL patients and are not suitable for the
diagnosis of this manifestation of the disease.
Conclusion: We suggest that both DAT and FAST are very practical diagnostic tools for the sero-
diagnosis of AVL under rural conditions as both serological tests do not require sophisticated
equipment, a cold chain and are very simple to perform.
Background
American visceral leishmaniasis (AVL) a protozoan dis-
ease caused by Leishmania chagasi parasites, constitutes a
major health problem in Brazil. In the last few years the
number of human cases of AVL in the metropolitan
region of Belo Horizonte (MRBH), state of Minas Gerais,
Brazil has increased, indicating an elevation in the trans-
mission rate of the disease [1]. Dogs and fox are consid-
ered to be the main reservoirs host for this parasite [2,3].
The diagnosis of AVL is based on clinical-epidemiological
characteristics, by microscopical demonstration of the
parasite in biopsies of aspirates, indirectly by serological
tests and culturing or molecular methods like the
polymerase chain reaction (PCR) [4-6]. Several
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techniques can be used for the sero-diagnosis of AVL. The
indirect fluorescence technique (IFAT) was the technique
of choice until 1974 [7,8]. Since then counter-current
immuno-electrophoresis and enzyme-linked immuno-
sorbent assay (ELISA) have been found to be powerful
tools for the sero-diagnosis of leishmaniasis [9]. In addi-
tion, several other serological tests have been developed.
The direct agglutination test (DAT) has proved to be a very
important sero-diagnostic tool combining high levels of
intrinsic validity and ease of performance [10-12]. The test
uses whole, stained promastigotes either as a suspension
or in a freeze-dried form [10,11,13,14]. By using the
freeze-dried antigen, logistic problems, such as the need
of a cold chain for storage of antigen, are avoided, making
the DAT very suitable for use under field conditions.
Although the direct agglutination test (DAT) for the sero-
diagnosis of visceral leishmaniasis has a high sensitivity
and specificity [6,13,14], it still has some limitations like
the relative long incubation time (18 h) and the need for
serial dilutions of blood or serum. In order to circumvent
these problems Schoone et al. [15] developed a fast agglu-
tination-screening test (FAST) for the rapid detection of
anti-Leishmania antibodies in serum samples and in blood
collected on filter paper. The FAST utilises only one serum
dilution (qualitative result) and requires 3 hours of incu-
bation. This makes the test very suitable for the screening
of large populations.
The increasing importance of AVL in man and its high
rates of lethality in the Metropolitan Region of Belo Hor-
izonte (MRBH) indicate that a rapid and relatively simple
method is needed for the routine diagnosis of this disease.
The objective of this study was to evaluate DAT and FAST
as potential AVL diagnostic methods using clinical sam-
ples from this region in Brazil.
Materials and methods
Serum samples
This study was carried out utilising serum samples from
different patients groups from metropolitan region of
Belo Horizonte (MRBH), Minas Gerais State and some
control samples from other regions (see below). Samples
and information of patients (age, sex, symptomatology,
clinical, address) were sent to the laboratory through the
existing health care system of MRBH, Minas Gerais, Brazil.
Written consent was obtained from the patient or their
relative for this study.
The following groups of samples were included in the
present study:
1. Serum samples of AVL patients parasitologically con-
firmed (microscopical examination from bone marrow
aspirate smears) (n = 16).
2. Serum samples of patients clinically suspected of AVL
(fever, spleen enlargement, pallor, weight loss), but not
parasitologically confirmed (n = 99).
3. Serum samples of patients presenting with active cuta-
neous leishmaniasis lesions (n = 85).
4. Serum samples of patients with confirmed Chagas' dis-
ease (n = 12)
5. Serum samples of patients (Uganda) with confirmed
African trypanosomiasis (n = 5)
6. Serum samples of patients (Kenya) with confirmed P.
falciparum malaria (n = 5)
7. Serum samples of confirmed toxoplasmosis patients
(The Netherlands) (n = 5)
8. Serum samples of apparently healthy individuals from
an AVL endemic region in Brazil (n = 19)
9. Serum samples of healthy blood donors from a non-
endemic region (The Netherlands; n = 5)
Serology
The presence of Leishmania antibodies in all the serum
samples was determined by FAST and DAT. A sub-set of
the samples (groups 1 – 3) were also analysed with IFAT.
Antigen for FAST and DAT were prepared as described ear-
lier [13,15]. The FAST was performed according to the
protocol described previously [15]. In brief, serum sam-
ples were diluted 1:100 in physiological saline (NaCl
0.85%) to which 0.78% β  – mercaptoethanol was added
in a V-shaped microtitre plate (Greiner, Germany). Next,
20 µl of this 1:100 dilution was transferred to another well
of the V-shaped microtitre plate and 20 µl FAST antigen (2
× 108 promastigotes/ml) was added. The plate was care-
fully shaken, covered with a lid and allowed to incubate
for 3 hours at room temperature after which the results
were read. Appropriate positive and negative controls
were always included on each plate.
The DAT was performed essentially as previously
described by [10,13]. In brief, the samples were diluted in
physiological saline (0.9% NaCl) containing 0.78% β  –
mercaptoethanol. Two-fold dilution series of the sera
were made in a V-shaped microtitre plate, starting at a
dilution of 1:100 (step 1) and going up to a maximum
serum dilution of 1:102.400 (step 11). Well 12 was used
as a negative control. Fifty µl DAT antigen (concentration
of 5 × 107 parasites per ml) was added to each well con-
taining 50 µl diluted serum and the results were read after
18 hours of incubation. The cut-off value of the DAT was
set at >1:800.Kinetoplastid Biology and Disease 2005, 4:4 http://www.kinetoplastids.com/content/4/1/4
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The IFAT was, due to logistic problems, only performed
on a selection of the serum samples using a commercial
kit for the diagnosis of human leishmaniasis (Fiocruz/
Bio-Manguinhos, Rio de Janeiro, Brazil). IFAT was per-
formed according to the instructions of the manufacturer
for detection of antibodies in serum diluted from 1:40 up
to 1:640.
Statistical analysis
The sensitivity and specificity of the DAT and FAST in the
present study were calculated as follows: Sensitivity = TP/
(TP+FN) × 100% and Specificity = TN/(TN+FP) × 100%.
Where TN represents true negative, TP true positive, FN
false negative and FP false positive. The sensitivity of the
two tests, FAST and DAT, was assessed with sera from con-
firmed AVL patients (n = 16). Sera of healthy controls (n
= 24) and sera of patients with confirmed other diseases
(n = 112) were used to determine the specificity of DAT
and FAST.
The degree of agreement between FAST, DAT and IFAT
was determined by calculating Kappa (κ ) values with 95%
confidence intervals using Epi-info version 6. Kappa val-
ues express the agreement beyond change and a κ  value of
0.21 – 0.60 represents a fair to moderate agreement, a κ
value of 0.60 – 0.80 represents a substantial agreement
and a κ >0.80 represents almost perfect agreement beyond
change [16]. The calculation of the degree of agreement
between DAT and FAST was based on all serum samples,
whereas the κ  values for DAT -IFAT and FAST – IFAT were
only based on the results obtained with the confirmed
and suspected AVL serum samples.
Results
The results of the serological analysis with DAT and FAST
are presented in Tables 1 and 2, respectively. The sensitiv-
ity of the DAT in the present study was calculated to be
100% and its specificity 97.8% (3 false positive results).
The FAST had a sensitivity of 100% and a specificity of
92.5% (11 false positive results). The results of the IFAT
testing are presented in Table 3. The sensitivity and specif-
icity of the IFAT could not be adequately calculated as a
sufficient number of negative samples was not analysed
with this test. It should be noted that IFAT tested 1 con-
firmed AVL patient negative and 7 patients only had a low
IFAT titre. In contrast, IFAT found about 50% of all con-
firmed ACL patients sero-positive, whereas neither DAT
nor FAST was able to detect antibodies in these serum
samples. The DAT found 77 out of 99 samples of patients
suspected (but not parasitologically confirmed) of AVL
positive. It was observed that 79/99 patients were FAST
positive and 84/99 patients were IFAT positive with serum
dilutions varying from 1:40 to 1:640.
A high degree of agreement (96%) was observed between
FAST and DAT (Table 4a). The agreement beyond change
(κ  value) was 0.92. In addition, substantial agreement was
observed between DAT and IFAT (93%; Table Table 4b) or
FAST and IFAT (94%; Table Table 4c), with κ  values of
0.75 and 0.80, respectively.
Discussion
In view of the public health importance of AVL and the
inherent difficulties of conventional diagnosis tech-
niques, we evaluated in the present study the performance
of the sero-diagnostic tests, DAT and FAST. Both test dis-
played a very high sensitivity and specificity corroborating
with previous studies [10,13-15]. It is noted that the sen-
sitivity of DAT and FAST observed in the present study was
determined using a relatively low number of confirmed
patients, and therefore 100% sensitivity is not claimed.
The antigen on which DAT and FAST are based is a strain
of L. donovani, whereas human and canine visceral leish-
maniasis in Brazil is caused by Leishmania chagasi, both
species belonging to the L. donovani complex. Apparently
Table 1: Direct agglutination test (DAT) results for anti-Leishmania antibodies in various patients groups.
Serial dilution series
Patient group ≤  800 1600 3200 6400 12800 25600 51200 102.400 Total (n)
1  c o n f i r m e d  A V L --1-4137 1 6
2 suspected AVL 22 - 3 9 8 15 5 37 99
3  c o n f i r m e d  C L 8 4 -1----- 8 5
4  c o n f i r m e d  C h a g a s '  d i s e a s e 1 0 2------ 1 2
5  c o n f i r m e d  t r y p a n o s o m i a s i s 5-------5
6  c o n f i r m e d  m a l a r i a 5-------5
7  c o n f i r m e d  t o x o p l a s m o s i s 5-------5
8  h e a l t h y  e n d e m i c  c o n t r o l s 1 9 ------- 1 9
9  h e a l t h y  n o n - e n d e m i c  c o n t r o l s 5-------5Kinetoplastid Biology and Disease 2005, 4:4 http://www.kinetoplastids.com/content/4/1/4
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the use of an heterologous antigen did not affect the per-
formance of both tests for the detection of anti-Leishmania
antibodies in Brazilian AVL patients. The DAT found all
parasitologically confirmed AVL patients positive at a
serum dilution of ≥  1:800, which was subsequently used
as the cut off dilution in the present study. This serum
dilution is comparable to the cut off dilutions found in
several other studies [13,14]. The FAST also found all con-
firmed cases positive, which should be the case as this test
is intended as a screening test that should not miss any
AVL patient. This result is even better than a previous eval-
uation of the FAST in which some cases were missed [15].
We have also compared the performance of IFAT with
DAT and FAST on serum samples of confirmed AVL cases
and suspects. The IFAT missed one confirmed patient that
had a very high DAT serum dilution. On the other hand,
IFAT found slightly more suspected ALV patients positive
(84/99) than DAT (77/99) or FAST (79/99) did. However,
there was in general a very good agreement between the
Table 2: Fast agglutination screening test (FAST) results for anti-Leishmania antibodies in various patients groups.
Patient group FAST negative Fast Positive Total (n)
1 – Confirmed AVL 0 16 16
2 – Suspected AVL 20 79 99
3 – Confirmed CL 82 3 85
4 – Confirmed Chagas' disease 6 6 12
5 – Confirmed trypanosomiasis 4 1 5
6 – Confirmed malaria 5 0 5
7 – Confirmed toxoplasmosis 5 0 5
8 – Healthy endemic controls 18 1 19
9 – Healthy non-endemic controls 5 0 5
Table 3: Indirect Immunofluoresence Test (IFAT) results for anti-Leishmania antibodies in serum of sub-set of the different patients 
groups (NR = no reaction).
Patient group NR 1:40 1:80 1:160 1:320 1:640 Positive/Total (n)
1 – Confirmed AVL 1 1 6 - 6 2 15/16
2 – Suspected AVL 15 7 20 20 23 14 84/99
3 – Confirmed ACL 37 3 23 12 9 1 48/85
Table 4: Comparison between DAT, FAST and IFAT using serum samples from suspected visceral leishmaniasis patients from the 
Belo Horizonte Metropolitan Region.
A. Comparison between DAT and FAST
FAST + FAST - Total
DAT + 96 0 96
DAT - 10 145 155
Total 106 145 251
Comparison between DAT and IFAT
IFAT + IFAT - Total
DAT + 92 1 93
DAT - 7 15 22
Total 99 16 115
C. Comparison between FAST and IFAT
IFAT + IFAT - Total
FAST + 94 1 95
FAST - 5 15 20
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performance of the three tests with regard to the seo-diag-
nosis of AVL. In contrast, both FAST and DAT found only
a very limited number of ACL cases sero-positive. IFAT
found approximately 50% of these cases positive, albeit
with generally very low serum titres. DAT and FAST based
on L. donovani antigen are not suitable for the sero-diag-
nosis of ACL [13].
Conclusion
As final remarks, we can conclude that DAT and FAST are
very suitable tools for the sero-diagnosis of AVL. Both tests
are easy to interpret, as well as being specific and sensitive.
The DAT is very practical under field or rural conditions,
as no specialised equipment is required nor a cold chain
is necessary for the storage of antigen. In addition, the
FAST requires only one serum dilution and the results can
be read within 3 hours. The FAST can be used to screen
large populations, for example in situations such as epi-
demics where large number of suspects are seen at the
clinic or cases where immediate treatment is necessary.
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